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Abstract
Background: Nowadays, there is a considerable bulk of evidence showing that ATP has a prominent role in the regulation of
human urinary bladder function and in the pathophysiology of detrusor overactivity. ATP mediates nonadrenergic-
noncholinergic detrusor contractions in overactive bladders. In vitro studies have demonstrated that uroepithelial cells and
cholinergic nerves from overactive human bladder samples (OAB) release more ATP than controls. Here, we compared the
urinary ATP concentration in samples collected non-invasively from OAB women with detrusor overactivity and age-
matched controls.
Methods: Patients with neurologic diseases, history of malignancy, urinary tract infections or renal impairment (creatinine
clearance ,70 ml/min) were excluded. All patients completed a 3-day voiding diary, a 24 h urine collection and blood
sampling to evaluate creatinine clearance. Urine samples collected during voluntary voids were immediately freeze-
preserved for ATP determination by the luciferin-luciferase bioluminescence assay; for comparison purposes, samples were
also tested for urinary nerve growth factor (NGF) by ELISA.
Results: The urinary content of ATP, but not of NGF, normalized to patients’ urine creatinine levels (ATP/Cr) or urinary
volume (ATP.Vol) were significantly (P,0.05) higher in OAB women with detrusor overactivity (n = 34) than in healthy
controls (n = 30). Significant differences between the two groups were still observed by boosting urinary ATP/Cr content
after water intake, but these were not detected for NGF/Cr. In OAB patients, urinary ATP/Cr levels correlated inversely with
mean voided volumes determined in a 3-day voiding diary.
Conclusion: A high area under the receiver operator characteristics (ROC) curve (0.741; 95% CI 0.62–0.86; P,0.001) is
consistent with urinary ATP/Cr being a highly sensitive dynamic biomarker for assessing detrusor overactivity in women
with OAB syndrome.
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Introduction
Overactive bladder (OAB) is a complex clinical syndrome based
on self-reported symptoms of urinary urgency associated with
incontinence in up to one-third of cases, usually accompanied by
daytime frequency and nocturia, in the absence of proven
infection or other obvious pathology [1]. It has been reported an
overall prevalence of 12,8% in women [2], and a significant
impact on patients quality of life [3]. The precise pathogenesis
underlying OAB remains to be clarified and might be multifac-
torial. OAB symptoms are often associated with detrusor
overactivity, which is diagnosed by invasive urodynamic testing
as involuntary contractions of the detrusor muscle during bladder
filling. Regrettably, the relationship between clinical symptoms
and urodynamic findings is not reliable [4,5]. In fact, procedure
constrains such as saline infusion rate and temperature, patient
position, and anxiety, may yield distinct urodynamic results [6],
which makes urodynamic confirmation of detrusor overactivity
with only limited clinical value regarding the severity or prognosis
of idiopathic OAB [7,8]. This renders urodynamic investigation
with suboptimal characteristics to evaluate OAB patients and urge
the search for new accurate, reliable and non-invasive tests to
predict detrusor overactivity and to assess patients’ therapeutic
outcome (reviewed in [9]).
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Recently, low grade inflammatory mediators, such as cytokines,
prostaglandin E2 (PGE2) and nerve growth factor (NGF), gained
significant attention as urinary biomarkers of detrusor overactivity.
Although they correlate with OAB symptom severity, they have
not been shown to have independent prognostic benefit (reviewed
in [10]) and they still cannot replace the standard filling cystometry
in standard clinical practice [9]. For instance, pilot studies indicate
that there is a wide variation of urinary NGF levels and not all
patients with OAB have elevated urinary NGF [11–13].
Purinergic transmission has increasingly been accepted as
having an important role in urinary tract dysfunction. It
encompasses both efferent and afferent paths of the voiding
reflex, and has particular relevance in the pathogenesis of
detrusor overactivity [14,15]. Several studies have reported that
urothelium releases ATP in response to mechanical and
chemical stimuli [16,17]. These stimuli evoke a discharge in
suburothelial low-threshold sensory nerves through P2X3
receptors activation, since sensory nerve excitation is substan-
tially reduced by P2X3 antagonists [18] and in P2X3 knock-out
mice [19], also the density of these receptors is increased in
patients with detrusor overactivity [20]. Conversely, intravesical
instillation of ATP increases bladder activity in a concentration
dependent manner [21]; intravesical ATP decreases bladder
capacity and micturition volume, with limited effect on detrusor
pressure. Recently, evidence has been emerging in support of a
role for suburothelial myofibroblasts in detrusor contraction,
which also express P2X and P2Y purinoceptors [22]. In
detrusor smooth muscle fibres, P2X1 receptor subtype expres-
sion is also markedly increased in unstable bladders (reviewed in
[15]). This implies that ATP is an important mediator of
bladder sensory/effector pathways.
Increased ATP release from the urothelium has also been
demonstrated in animal models of OAB [23–25]. In vitro studies
conducted in our lab, as well as by others, showed that
uroepithelial cells and cholinergic nerves from overactive or
obstructed human bladder samples release more ATP than
controls [26,27]. Interestingly, strong evidences suggest that the
primary source of ATP in the human bladder is the urothelium
[28]. Thus, this study was prospectively designed to measure the
urinary concentration of ATP in OAB women tested positively for
detrusor overactivity and in age-matched controls to assess the
putative role of ATP as a non-invasive biomarker of detrusor
overactivity in OAB patients. For comparison purposes, urine
samples were also tested for NGF levels.
Methods
Patients and Procedures
This study and all its procedures were approved by the Ethics
Committees of Centro Hospitalar do Porto (CHP) and of Instituto
de Cieˆncias Biome´dicas de Abel Salazar (Medical School) of the
University of Porto (ICBAS-UP). All patients signed an informed
consent prior to examinations and for using the biological
material. The investigation conforms to the principles outlined
in the Declaration of Helsinki. A total of 70 women were enrolled
in this study, including 34 patients with overactive bladder
symptoms and detrusor overactivity (aged 28–84 years, mean
57613 years) and 36 controls (aged 34–67 years, mean 5269
years) that included asymptomatic volunteers recruited among the
hospital staff and patients with mild stress incontinence without
overactive bladder symptoms and normal urodynamics (see
Figure 1). This was a prospective study. Patients were consecu-
tively selected (January 2010–June 2011) from outpatients
consulting the Department of Urology of CHP complaining from
urgency (at least one episode daily), frequency (.8 voids/day) and
reduced bladder capacity (mean voided volume ,300 ml).
Detrusor overactivity was confirmed in all women with OAB by
urodynamic testing performed within 12 months before collection
of biological samples and the results were analysed in accordance
to the criteria of the International Continence Society (ICS)
defining detrusor overactivity as involuntary and spontaneous
contractions of the detrusor occurring during the storage phase.
Patients with history of malignancy, pelvic radiotherapy, neuro-
logic disease, any systemic or inflammatory condition, active
urinary tract infections, renal impairment (creatinine clearance
,70 ml/min) or taking any medication that could affect bladder
function within the 14 days time period before sample collection
were excluded; pregnant women were also excluded from the
study. Patients with incomplete emptying (post-void residual
volume .100 ml) and with voiding dysfunction (Pdet at maximal
flow .60 mm H2O) were also not included in the study. All
patients completed a 3-day voiding diary, a 24 h urine collection
and blood sample collection to estimate creatinine clearance.
Subjects were asked to void at normal desire into a sterile cup.
Thus, urine sample collection in this work was non-invasive, which
contrasts with previous studies that used urodynamic fluid voided
after cystometric saline bladder filling [29,30]. Two consecutive
voids were used; the first void was collected upon patients’ arrival
to consultation and the second void was collected after allowing
patients to drink 500 mL of water ad libitum. Voided volume was
recorded and post-void residual volume was estimated by
ultrasonography. Mid-stream urine samples were divided into
three tubes; one for sediment examination, another for creatinine
measurement and a third was immediately freeze-dried in liquid
nitrogen and preserved at 280uC until ATP determination. ATP
values were normalized according to urinary creatinine (Cr) values
to reduce sample variation and to discard kidney influence on
ATP levels. ATP/Cr ratios were compared between patients and
controls.
Measurement of Urinary Creatinine
The quantitative determination of urinary creatinine was
performed in vitro on a Cobas Integra 800 analyser using the
kinetic colorimetric Creatinine Jaffe´ Gen.2 assay according to the
manufacturers’ instructions (Roche Diagnostics GmbH, Mann-
heim, Germany).
Measurement of Urinary ATP
Undiluted urine samples were defrosted till 25uC and afterwards
centrifuged at 3000 g at room temperature for 20 seconds to
remove cellular debris. The supernatant was separated. A mixture
of luciferine-luciferase was added according to the manufacturer
instructions using the ATP Bioluminescence Assay Kit HS II
(Roche Applied Science Indianapolis, Indiana, USA). ATP
detection was evaluated using a multi-mode microplate reader
(Synergy HT, BioTek Instruments Inc., Vermont, USA) controlled
via BioTek’s Gen5TM Data Analysis Software. Sample biolumi-
nescence was compared to that of standard amounts of ATP used
in the same concentration range; standard ATP samples were
prepared daily. All samples were run in duplicate. The minimum
ATP detection limit in these experimental conditions was 10212 M
(10216 moles in 100 ml samples) and luminescence correlated
linearly to ATP concentration till 1026 M. Each urine sample
remaining was used to quantify the lactate dehydrogenase (LDH,
EC 1.1.1.27) activity [31]. LDH is an intracellular enzyme which
is commonly used as an indicator of cell integrity providing that its
values are kept at a low level.
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Measurement of Urinary NGF
Measurement of urinary NGF level was also done in a subset of
urine samples used for ATP determination (technique reviewed by
[11]). After defrosting and homogenization, samples were used to
measure NGF levels by the ELISA method, according to the
manufacturer instructions. We determined urinary NGF concen-
tration using the Emax ImmunoAssay System (Promega, Madison,
EUA), a specific ELISA kit that has a minimum sensitivity of
7.8 pg/ml. All samples were run in duplicate. NGF values were
also normalized according to urinary creatinine (Cr) values to
reduce sample variation; obtained NGF/Cr ratios were compared
between patients and controls.
Routine measurements of blood and urine samples were
performed in a blind manner by independent observers from
Servic¸o de Quı´mica Clı´nica - Centro Hospitalar do Porto (CHP,
Porto). Urinary ATP and NGF contents were tested in blind
samples at Laborato´rio de Farmacologia e Neurobiologia (UMIB/
ICBAS-UP). NGF measurements were re-tested and confirmed
with the methodology in use at the Department of Urology,
Centro Hospitalar de S. Joa˜o and Faculty of Medicine, University
of Porto.
Statistical Analysis
Statistical analyses were performed using GraphPad Prism 5.04
software (La Jolla, USA). Results are reported as mean values 6
standard deviation (SD) of samples collected during the first void,
unless stated otherwise. Kolmogorov-Smirnov test was used to
check for normality of data distribution. Unpaired Student’s t-test
with Welch’s correction and Mann-Whitney U-test were used for
statistical analysis between groups when parametric or nonpara-
metric data was considered, respectively. For multiple compari-
sons, one-way ANOVA nonparametric Kruskal-Wallis test with
Dunn’s post test modification was used. Correlation between
variables were analysed using the Spearman test. P,0.05 (two-
tailed) values were considered statistically significant.
Results
In this study, efforts have been made to match age among OAB
women with detrusor overactivity and the control group (P.0.05,
see Table 1), since it has been described that urinary ATP may
increase in older subjects [32]; see in Table 2 the positive
correlation between age and ATP/Cr levels found in our series
(Spearman test, r = 0.380, P,0.05). The two groups were also
essentially similar (P.0.05) regarding creatinine clearance, urine
pH and urinary LDH activity (Table 1). Early reports indicate that
females with detrusor overactivity may have significantly lower
urinary pH than controls [33]. This tendency did not reach
statistical significance (P.0.05) in this series excluding any possible
influence the pH might have on urinary ATP and NGF content in
control and OAB patients. As expected, maximum and mean
voided volumes determined from the 3-day voiding diary were
significantly (P,0.05) lower in OAB patients than in controls
(Table 1).
Urinary ATP levels were significantly (P,0.05) higher in OAB
women with detrusor overactivity as compared to the control
group (Table 1 and Figure 2A). This was also verified when the
ATP content was normalized either to urine creatinine levels
(ATP/Cr, pmol/mg) (Figure 2C) or to the urinary volume
(ATP.Vol, pmol) (Table 1); the latter reflects better the raw
amount of ATP accumulated in the bladder during urine storage.
Since no significant changes (P.0.05) were observed in the activity
of the intracellular enzyme, LDH, in urine samples from OAB
Figure 1. Flow diagram of patients’ selection.
doi:10.1371/journal.pone.0064696.g001
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patients and age-matched controls (Table 1) and no correlation
was found between ATP/Cr levels and LDH activity (Table 2),
urinary cells damage might not account for changes detected in
ATP levels in OAB patients and controls.
The Receiver Operating Characteristics (ROC) graphs are
commonly used in medical decision making. ROC graphs have
long been used in signal detection theory to depict the tradeoff
between hit rates and false alarm rates of classifiers [34]. A high
area under the ROC curve (0.741; 95% CI 0.62 to 0.86; P,0.001)
is consistent with urinary ATP/Cr being a highly sensitive
biomarker for discriminating OAB women with detrusor overac-
tivity (Figure 2E).
Although NGF levels normalized to creatinine content in the
urine (NGF/Cr, pg/mg) tended to increase in OAB patients as
compared to controls, this trend did not reach statistical
significance (P.0.05) (Figure 2D, see also [35]; cf. [36]). We
found no significant correlation between ATP/Cr and NGF/Cr
levels measured in parallel from samples collected from OAB
patients (Spearman test, r = 0.221, P.0.05), despite the two
compounds showed some degree of correlation in the control
group (Table 2). We did not found statistically significant
differences in the concentration of NGF (pg/ml) measured in
urine samples from control and OAB patients (Figure 2B) and the
urinary NGF accumulation during bladder storage normalized to
the urinary volume (NGF.Vol, ng) was even lower in OAB patients
than in controls (Table 1). We detected a wide variation (and lack
of correlation) of urinary NGF/Cr levels in paired samples
collected from control individuals between the 1st and the 2nd void
obtained after water intake, which was no better in women with
OAB (Figure 3B and 3D, see also Table 2). These results suggest
that NGF determination is highly dependent on the urinary
volume (Table 1), a situation that has not been reported in
previous studies. The statistical analysis presented in Table 1,
shows that the mean urinary NGF content normalized to voided
volume decreased significantly in OAB patients as compared to
healthy controls as a consequence of forcing the desire to void by
water intake (2nd void). This finding is in clear contrast to that
occurring with urinary ATP; the urinary content of the nucleotide
boosted in the 2nd void upon increasing the urinary volume by
drinking water at libitum (for correlation analysis, see Table 2). It is
worth noting that water intake (after 1st void) increases the
sensitivity of urinary ATP determinations in OAB patients versus
controls (Table 1, ROC curve area = 0.769; 95% CI = 0.64–0.90;
P,0.001).
Figure 4A, shows that urinary ATP/Cr levels correlate inversely
with the mean voided volume determined in a 3-day voiding diary
in OAB patients. In other words, urinary ATP/Cr was maximal in
OAB patients who reported a mean voided volume less than
100 ml (observed in 9 out of a total of 34 patients). These findings
contrast with data from the control group where ATP levels
normalized to urine creatinine content (ATP/Cr, pmol/mg)
positively correlates with the mean voided volume (Spearman
test, r = 0.522, P,0.01) (see Figure 4A) and fully agree with the
concept that physiological distension of the urothelium releases
ATP into the lumen of the bladder [16,17]. No other parameter
analyzed in this study changed significantly (P.0.05) between the
Table 1. Characteristics of OAB patients and controls. P,0.05
(unpaired Student’s t-test with Welch’s correction) represent
significant differences from controls.
Controls
(n =36)
mean±SD
OAB (n=34)
mean±SD P
Age (yrs) 51.868.7 57.3612.8 0.055
Creatinine clearance (ml/min) 98.969.6 116.767.1 0.171
Urinary pH 6.760.4 5.960.3 0.135
Urinary LDH (U/ml) 12.163.7 6.861.2 0.174
3-Day Voiding Diary:
Minimum Void Volume (ml) 86.6621.3 73.7623.5 0.263
Maximum Void Volume (ml) 425.06121.5 326.1685.3 0.009
Mean Void Volume (ml) 198.6631.1 159.9640.2 0.033
1st Void (upon arrival):
Vol. 1st Void (ml) 203.3656.5 210.8661.7 0.810
Urinary ATP 1st Void (pM) 26476403 700461228 0.001
Urinary ATP x Vol. 1st Void (pmol) 707.86139.6 1556.16290.9 0.012
Urinary ATP/Cr 1st Void (pmol/mg) 7.261.7 27.568.3 0.022
Urinary NGF 1st Void (pg/ml) 530.56136.2 467.56193.0 0.397
Urinary NGF x Vol. 1st Void (ng) 117.9642.3 67.5615.7 0.126
Urinary NGF/Cr 1st Void (pg/mg) 64.0613.6 109.5629.0 0.162
2nd Void (after water intake):
Volume of 2nd Void (ml) 310.0677.5 260.9666.9 0.181
Urinary ATP 2nd Void (pM) 57006978 1057761533 0.006
Urinary ATP x Vol. 2nd Void (pmol) 2003.16366.4 3008.46517.5 0.022
Urinary ATP/Cr 2nd Void (pmol/mg) 42.567.2 89.1619.3 0.029
Urinary NGF 2nd Void (pg/ml) 526.06227.1 296.26128.4 0.185
Urinary NGF x Vol. 2nd Void (ng) 82.7624.0 39.2610.4 (0.045)
Urinary NGF/Cr 2nd Void (pg/mg) 86.0617.4 121.7633.8 0.352
doi:10.1371/journal.pone.0064696.t001
Table 2. Correlation between variables analysed using the Spearman test. P,0.05 values were considered statistically significant.
Controls
r (Spearman approx.)
P
value
OAB Patients
r (Spearman approx.)
P
value
ATP/Cr vs NGF/Cr 0.378 0.023 0.221 0.118
ATP/Cr (1st vs 2nd voids) 0.774 ,0.0001 0.381 0.013
NGF/Cr (1st vs 2nd voids) 20.109 0.291 0.307 0.046
Age vs ATP/Cr 0.380 0.019 20.198 0.131
Age vs NGF/Cr 0.217 0.134 20.115 0.165
LDH vs ATP/Cr 20.054 0.399 0.249 0.085
LDH vs NGF/Cr 20.185 0.199 20.450 0.006
doi:10.1371/journal.pone.0064696.t002
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Figure 2. Urinary ATP and NGF levels determined before (A: ATP, nM and B: NGF, pg/ml) and after normalization to urine creatinine
content (C: ATP/Cr, pmol/mg and D: NGF, pg/mg) in women with OAB (n=34) and age-matched controls (n=36). Columns are mean
values6 standard deviation (SD). *P,0.05 (unpaired Student’s t-test with Welch’s correction) represent significant differences from controls. In E and
F, represented are the receiver-operator characteristics (ROC) curves of urinary ATP/Cr and urinary NGF/Cr in OAB patients, respectively. Please note
that, for this cohort, ATP/Cr has a better area under de curve (AUC = 0.7407; 95% confidence interval (CI) = 0.62–0.86; P,0.001) than NGF/Cr
(AUC = 0.5391; 95% CI = 0.39–0.69; P,0.001).
doi:10.1371/journal.pone.0064696.g002
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three subgroups identified using the mean voided volume as
criteria, namely age and urine measurements of creatinine, pH
and LDH activity. Thus, finding a correlation between ATP/Cr
levels and the mean voiding volume may be taken as a marker for
the severity of detrusor overactivity and should be considered of
clinical relevance in the follow-up of OAB syndrome. Using
200 ml as a cutoff value, we found that urinary NGF/Cr levels in
OAB patients were significantly (P,0.05) higher than those found
in the control group, but this difference disappeared in less severe
forms of bladder overactivity (Figure 4B).
In this series, 25% of the women with detrusor overactivity
complained of urgency without incontinence (OAB dry), whereas
the remaining group (75%) had urgency urinary incontinence
(OAB wet). Figure 5 shows that urinary ATP/Cr, but not NGF/
Cr, levels were significantly (P,0.05) higher than controls in
women with OAB, despite they have been characterized as OAB
dry or OAB wet. No significant differences (P.0.05) were,
however, detected in urinary ATP/Cr and NGF/Cr levels among
OAB patients of the two subcategories.
Discussion
To our knowledge, this is the first study so far designed to
evaluate synchronous changes of both ATP and NGF levels in
urine samples collected, non-invasively, during voiding at normal
desire by OAB women with detrusor overactivity and age-
matched controls. Data shows that ATP levels were significantly
higher in OAB women with detrusor overactivity than in the
control group and this was observed when ATP levels were
normalized either to urine creatinine content (ATP/Cr, pmol/mg)
or to the urinary volume (ATP.Vol, pmol). A high area under the
ROC curve (0.741; 95% CI 0.62–0.86; P,0.001) indicates that
urinary ATP/Cr may be a highly sensitive biomarker for
discriminating OAB women with detrusor overactivity. In this
series, we failed to obtain a similar pattern regarding urinary NGF
measurements. Although we found a tendency for NGF normal-
ized to urine creatinine content (NGF/Cr) to increase in OAB
patients as compared to controls, this tendency did not reached
statistical significance (P.0.05). Moreover, no significant correla-
Figure 3. Analysis of ATP/Cr (pmol/mg) and NGF/Cr (pg/mg) content in paired urine samples collected from control women (A and
B) and OAB patients (C and D) at arrival to the consultation (1st void) and after water intake (2nd void). See Table 2, for correlation
between variables (Spearman test).
doi:10.1371/journal.pone.0064696.g003
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tion between urinary ATP/Cr and NGF/Cr levels was found in
the samples collected from OAB women with detrusor overactiv-
ity.
Interestingly, ATP levels measured in paired samples collected
after water intake (2nd void) consistently exceeded those verified in
the samples collected upon arrival to the consultation (1st void),
both in controls and OAB patients. That is, for a given patient or
control, ATP/Cr content in the 2nd void boosted and significantly
correlated with the amount detected in the previous (1st) void. This
situation was clearly different if one considers NGF/Cr measure-
ments. In keeping with the assumption that urinary NGF content
is sensitive to urinary volume variations, we found a wide
dispersion between measurements of NGF in paired samples
obtained from 1st and 2nd voids, both in controls and in patients
with OAB. Our findings fully agree with in vitro experiments
demonstrating that mechanical distension of bladder urothelium
from patients with OAB release significantly more ATP than
controls [26]. Thus, water intake may increase the sensitivity of
urinary ATP measurement as a biomarker of detrusor overactivity
in OAB patients (ROC curve area = 0.769; 95% CI = 0.64–0.90;
Figure 4. Relationship between urinary (A) ATP/Cr (pmol/mg) and (B) NGF/Cr (pg/mg) content and the mean voided volume
determined in a 3-day voiding diary for women with OAB and age-matched controls. Columns are mean values6 standard deviation (SD)
from n number of individuals (shown in parenthesis). *P,0.05 (unpaired Student’s t-test with Welch’s correction) represent significant differences
from controls.
doi:10.1371/journal.pone.0064696.g004
Figure 5. Urinary (A) ATP/Cr (pmol/mg) and (B) NGF/Cr (pg/mg) content in women with detrusor overactivity complaining only of
urgency (OAB dry, n=7) and of urgency associated with urge urinary incontinence (OAB wet, n=21) as compared to age-matched
controls (n =36). Columns are mean values 6 standard deviation (SD). *,**P,0.05 (one-way ANOVA with Dunn’s multiple comparison test)
represent significant differences from controls and between OAB dry and OAB wet subgroups, respectively.
doi:10.1371/journal.pone.0064696.g005
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P,0.001). Given that the mean voided volume during the
provocative 2nd void significantly increases with respect to the 1st
void one would expect that the concentration of the nucleotide
should dilute accordingly, yet this was not the case probably
because raw ATP production by bladder distension exceeds the
water dilution factor, particularly in OAB patients. This was
verified even though urinary ATP measured in this study might
have been underestimated due to the hydrolysis of the nucleotide
by ecto-NTPDases bound to urothelial cells during urine bladder
storage. Thus, the more frequent the voids (e.g. OAB patients with
detrusor overactivity) the higher urinary ATP levels should be
measured. Despite this, we measured higher than control levels of
ATP in urine samples collected from OAB patients upon arrival to
the consultation (1st void) where no significant differences were
detected in the voided volume and inferred time to void (see
Table 1). ATP may, thus, be regarded as a novel and important
dynamic urinary biomarker of detrusor overactivity which levels
reflect adequately bladder distension under pathological condi-
tions.
Several mechanisms may account for increased ATP levels in
the urine of OAB women with detrusor overactivity. Hypertrophy
and hyperplasia of the urothelium and underlying smooth muscle
layers are frequently observed in overactive bladders. Thus, OAB
patients might have increased urinary ATP levels produced by
thickening of the epithelium taking into account that uro-
epithelium is in close contact with the urine and is a major source
of the nucleotide in the bladder [26,27]. Whether urothelial cells
per se release more ATP in OAB patients than in healthy controls
remains to be determined. In addition, it is known that
parasympathetic nerves from overactive or obstructed human
bladder strips release more ATP than controls [15,26,27].
Enhanced urinary ATP content may also result from impairment
of ecto-NTPDase activity observed in cells from OAB patients, as
this finding may determine slower nucleotide inactivation kinetics
in the bladder wall and its urinary accumulation [37,38].
Data from this study demonstrate that urinary ATP/Cr levels
correlated inversely with the mean voided volume obtained in a 3-
day voiding diary applied to OAB patients. Although the urinary
content of the nucleotide corrected to the creatinine level (ATP/
Cr) was consistently higher in samples from OAB patients than in
age-matched controls, differences tend to decrease when the
clinical condition of the patients was less severe (e.g. mean voided
volume higher than 200 ml). This tendency fully agrees with the
lack of differences in the concentration of ATP released during
cystometric bladder filling in women with mild bladder pain
syndrome and controls [30]. Previous reports also demonstrated
an inverse correlation between first desire to void and ATP
concentration in the voided urodynamic fluid collected from OAB
patients during cystometry investigation [29]. Both findings are
consistent with the hypothesis that ATP has a prominent role
modulating the early filling sensation in patients with OAB, which
yields to low bladder volumes at first desire to void and symptoms
of urgency, frequency and reduced bladder capacity presented by
patients of this series. Thus, higher concentrations of ATP would
produce early voiding reflexes in OAB patients as suggested in this
study. Recently, Sugaya and collaborators [32] investigated the
urinary ATP/Cr ratio in a population of 30 women with OAB
(aged 6968 years old) and 6 younger female controls (aged 3766
years old). The ATP/Cr ratio in the Sugaya’s study was about one
log unit lower than that obtained in our work, probably because
cryopreservation of urine samples was not undertaken before
readings. These authors did not found statistically significant
differences in the urinary ATP content between the two groups,
yet patients with higher ATP/Cr ratio had more severe symptoms
and worse quality of life scores than the group exhibiting lower
urinary ATP content, which fully agrees with our findings.
Moreover, they reported that ATP/Cr levels significantly
decreased after treatment with anti-muscarinic drugs and the
improvement of lower urinary tract symptoms was greater for
patients with a high baseline urinary ATP/Cr level [32]. These
findings suggest that urinary ATP may be a marker of disease
severity and might also be used to predict response to clinical
intervention. Preliminary results from our group indicate that
symptoms relief after intravesical botulinum toxin type A
application in six female patients with detrusor overactivity of this
series was accompanied by marked improvement of lower urinary
tract symptoms along with a complete regression of urinary ATP/
Cr to control levels (unpublished observations).
By far the most studied biomarker of OAB has been NGF, as
this neurotrophin is highly expressed in the urothelium and
suburothelial region of patients with bladder dysfunction (reviewed
in [11,13,36]). There is some evidence from these pilot clinical
studies using small patient populations that urinary NGF excretion
is also elevated in patients with OAB. This tendency was also
observed in this series, yet statistical significance was only obtained
for women with the most severe forms of bladder overactivity
reporting mean urinary volumes lower than 200 ml in the 3-day
voiding diary. However, the peptide may be a downstream
element of several bladder pathologies that may occur without
urinary urgency (e.g. bladder inflammation, outlet obstruction,
urolithiasis, neoplasia) (reviewed in [11,13]). This may cause
urinary NGF concentration to vary considerably amongst patients
with similar complaints, yet it may still find some utility to assess
OAB management as urinary NGF decreased after non-pharma-
cological and pharmacological treatments (reviewed in [11,36]).
Preliminary results published in the literature showed a superior
accuracy of brain derived neurotrophic factor (BDNF) over NGF
in diagnosing detrusor overactivity [36]. In contrast to NGF, a
direct release of BDNF from urothelial or smooth muscle cells was
never demonstrated and one cannot ignore that other organs
besides the bladder may also release neurotrophic factors [39,40].
Before adopting neurotrophins as urinary biomarkers of detrusor
overactivity, one must also consider several limitations, in addition
to the general lack of information about the levels of urinary
neurotrophins in normal individuals. Methodological limitations
include (a) the variation of urinary NGF and BDNF measurements
by enzyme-linked immunoabsorbent assay (ELISA), as this
method is not routinely available and requires technical expertise;
(b) the binding of neurotrophins to proteins or cells potentially
present in the urine of patients; and (c) the specificity of various
antibodies against NGF and BDNF precursors, which may add
variability to measured urinary neurotrophins. In addition, the
reported dependence of urinary NGF content on variations of the
voided volume (this study) and bladder distension [11], as well as
the lack of studies indicating that there is a clear-cut clinical
correlation between neurotrophin levels in urine samples and the
severity of detrusor overactivity, may contribute to question their
sensitivity to identify individuals with specific bladder pathologies
or patients with detrusor overactivity.
In this regard, ATP has a very simple, inexpensive and highly
reliable measurement method, the luciferin-luciferase biolumines-
cence assay. Technical limitation relies on the need for snap-freeze
urine samples immediately after collection to avoid ATP
degradation during storage. Moreover, urinary ATP is influenced
by bacterial infection, kidney dysfunction and malignancy, so care
must be taken to exclude such factors. In contrast to neurotro-
phins, differences between OAB patients and controls are
independent on the urinary volume and, in fact, sensitivity of
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urinary ATP measurements in OAB patients may be enhanced by
urine production and consequent bladder filling by water intake.
This study proved that there is a positive correlation between
urinary ATP levels and clinical symptoms evaluated by simply
adding a 3-day voiding diary to analytical tests. Surprisingly or
not, we found no statistical significant (P.0.05) differences
between urinary ATP/Cr levels in OAB patients complaining of
urgency without incontinence (OAB dry) and those reporting
incontinence urinary urgency (OAB wet). This supports the notion
that incontinence is inconsistently correlated and may have a
pathophysiological mechanism distinct from detrusor overactivity,
which might be independent from ATP bladder production.
Because several mechanisms may be involved in the pathophys-
iology of the OAB syndrome, one cannot exclude the benefit of
using a panel of urinary biomarkers (including neurotrophins) to
target detrusor overactivity and intervention follow-up. Unfortu-
nately, we found no correlation between ATP/Cr and NGF/Cr
levels in urine samples collected from woman with OAB in this
series.
In conclusion, our results support an important putative role of
ATP in the pathogenesis of detrusor overactivity. Data showed
that OAB women with detrusor overactivity have high urinary
levels of ATP compared to controls and that the nucleotide levels
increase with water intake. The increased concentration of ATP in
the urine of OAB patients is probably due to enhanced ATP
release from proliferating urothelium, since uroepithelial cells are
considered the primary source of ATP in the human bladder [28].
This hypothesis agrees with previous studies using experimental
models of bladder disorders exhibiting enhanced release of ATP
from the urothelium [41,42]. Moreover, in vitro studies demon-
strated that uroepithelial cells from overactive human bladder
samples release more ATP than controls and that the release of the
nucleotide was resistant to blockade of neuronal activity with
tetrodotoxin [26,27]. Decreased ATP metabolism could also
explain high levels of ATP in the urine of OAB patients as
compared to controls. Reports from our and others groups, have
shown that ATP catabolism is hindered in the bladder of patients
with outlet obstruction and detrusor overactivity [27,37,38], which
could also be the case of women with OAB. Thus, our findings are
consistent with urinary ATP being a putative dynamic biomarker
of detrusor overactivity in women with OAB. Non-invasive
urinary ATP measurements may represent an improvement from
other diagnostic and follow-up approaches requiring urodynamic
investigations. Future studies are needed to further examine
whether urinary ATP can also be used as a prognostic factor and
to assess the therapeutic outcome in OAB women with detrusor
overactivity.
Acknowledgments
NGF measurements were re-tested and confirmed with the methodology in
use at the Department of Urology, Centro Hospitalar de S. Joa˜o and
Faculty of Medicine, University of Porto; for that, we gratefully
acknowledge the collaboration of Mr Se´rgio Carvalho-Barros and
Professor Francisco Cruz. We acknowledge Margarida Duarte-Arau´jo
(DVM, PhD) for collaborating in preliminary ATP measurements. We also
thank Mrs. M. Helena Costa e Silva and Belmira Silva for technical
assistance.
Author Contributions
Conceived and designed the experiments: MSR IS OO SF PCS.
Performed the experiments: MSR IS OO SF MJR JCO PCS. Analyzed
the data: MSR IS OO SF PCS. Contributed reagents/materials/analysis
tools: MSR IS MJR JCO PCS. Wrote the paper: MSR IS PCS.
References
1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, et al. (2002) The
standardisation of terminology of lower urinary tract function: report from the
Standardisation Sub-committee of the International Continence Society.
Neurourol Urodyn 21: 167–178.
2. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, et al. (2006) Population-
based survey of urinary incontinence, overactive bladder, and other lower
urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50:
1306–1314.
3. Coyne KS, Sexton CC, Kopp ZS, Ebel-Bitoun C, Milsom I, et al. (2011) The
impact of overactive bladder on mental health, work productivity and health-
related quality of life in the UK and Sweden: results from EpiLUTS. BJU Int
108: 1459–71.
4. Bates CP, Whiteside CG, Turner-Warwick R (1970) Synchronous cine-pressure-
flow-cysto-urethrography with special reference to stress and urge incontinence.
Br J Urol 42: 714–723.
5. Hashim H, Abrams P (2006) Is the bladder a reliable witness for predicting
detrusor overactivity? J Urol 175: 191–194.
6. Brostrom S, Jennum P, Lose G (2002) Short-term reproducibility of cystometry
and pressure-flow micturition studies in healthy women. Neurourol Urodyn 21:
457–460.
7. Nitti VW, Rovner ES, Bavendam T (2010) Response to fesoterodine in patients
with an overactive bladder and urgency urinary incontinence is independent of
the urodynamic finding of detrusor overactivity. BJU Int 105: 1268–1275.
8. Rovner E, Kennelly M, Schulte-Baukloh H, Zhou J, Haag-Molkenteller C, et al.
(2011) Urodynamic results and clinical outcomes with intradetrusor injections of
onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in
idiopathic overactive bladder. Neurourol Urodyn 30: 556–562.
9. Farag FF, Heesakkers JP (2011) Non-invasive techniques in the diagnosis of
bladder storage disorders. Neurourol Urodyn 30(8): 1422–8.
10. Cartwright R, Afshan I, Derpapas A, Vijava G, Khullar V (2011) Novel
biomarkers for overactive bladder. Nat Rev Urol 8(3): 139–45.
11. Kuo HC, Liu HT, Chancellor MB (2010) Urinary nerve growth factor is a better
biomarker than detrusor wall thickness for the assessment of overactive bladder
with incontinence. Neurourol Urodyn 29(3): 482–7.
12. Liu HT, Chen CY, Kuo HC (2010) Urinary nerve growth factor levels in
overactive bladder syndrome and lower urinary tract disorders. J Formos Med
Assoc 109(12): 862–78.
13. Ochodnicky´ P, Cruz CD, Yoshimura N, Michel MC (2011) Nerve growth factor
in bladder dysfunction: contributing factor, biomarker, and therapeutic target.
Neurourol Urodyn 30(7): 1227–1241.
14. Ruggieri MR Sr (2006) Mechanisms of disease: role of purinergic signaling in the
pathophysiology of bladder dysfunction. Nat Clin Pract Urol 3: 206–215.
15. Burnstock G (2011) Therapeutic potential of purinergic signalling for diseases of
the urinary tract. BJU Int 107: 192–204.
16. Ferguson DR, Kennedy I, Burton TJ (1997) ATP is released from rabbit urinary
bladder epithelial cells by hydrostatic pressure changes–a possible sensory
mechanism? J Physiol (London) 505: 503–511.
17. Wang EC, Lee JM, Ruiz WG, Balestreire EM, von Bodungen M, et al. (2005)
ATP and purinergic receptor-dependent membrane traffic in bladder umbrella
cells. J Clin Invest 115: 2412–2422.
18. Ito K, Iwami A, Katsura H, Ikeda M (2008) Therapeutic effects of the putative
P2X3/P2X2/3 antagonist A-317491 on cyclophosphamide-induced cystitis in
rats. Naunyn Schmiedeberg’s Arch Pharmacol 377: 483–490.
19. Cockayne DA, Hamilton SG, Zhu QM, Dunn PM, Zhong Y, et al. (2000)
Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-
deficient mice. Nature 407: 1011–1015.
20. Moore KH, Gilpin SA, Dixon JS, Richmond DH, Sutherst JR (1992) Increase in
presumptive sensory nerves of the urinary bladder in idiopathic Detrusor
instability. Br J Urol 70(4): 370–2.
21. Pandita RK, Andersson KE (2002) Intravesical adenosine triphosphate
stimulates the micturition reflex in awake, freely moving rats. J Urol 168:
1230–1234.
22. Fry CH, Sui GP, Kanai AJ, Wu C (2007) The function of suburothelial
myofibroblasts in the bladder. Neurourol Urodyn 26(6 Suppl): 914–919.
23. Khera M, Somogyi GT, Kiss S, Boone TB, Smith CP (2004) Botulinum toxin A
inhibits ATP release from bladder urothelium after chronic spinal cord injury.
Neurochem Int 45: 987–993.
24. Smith CP, Vemulakonda VM, Kiss S, Boone TB, Somogyi GT (2005)
Enhanced ATP release from rat bladder urothelium during chronic bladder
inflammation: effect of botulinum toxin A. Neurochem Int 47: 291–297.
25. Munoz A, Smith CP, Boone TB, Somogyi GT (2011) Overactive and
underactive bladder dysfunction is reflected by alterations in utothelial ATP
and NO release. Neurochem Int 58: 295–300.
26. Kumar V, Chapple CR, Rosario D, Tophill PR, Chess-Williams R (2010) In
vitro release of adenosine triphosphate from the urothelium of human bladders
ATP Is a Urinary Biomarker of Overactive Bladder
PLOS ONE | www.plosone.org 9 May 2013 | Volume 8 | Issue 5 | e64696
with detrusor overactivity, both neurogenic and idiopathic. Eur Urol 57: 1087–
1092.
27. Silva-Ramos M, Silva I, Duarte-Arau´jo M, Magalha˜es-Cardoso T, Lafuente-de-
Carvalho J, et al. (2010) Loss of balance between excitatory P2X3 and inhibitory
A1 receptors contribute to cholinergic hyperactivity in obstructed human
bladder. Basic Clin Pharmacol Toxicol 107: 2397.
28. Kumar V, Chapple CC, Chess-Williams R (2004) Characteristics of adenosine
triphosphate release from porcine and human normal bladder. J Urol 172: 744–
747.
29. Cheng Y, Mansfield KJ, Allen W, Walsh CA, Burcher E, et al. (2010) Does
adenosine triphosphate release into voided urodynamic fluid contribute to
urgency signaling in women with bladder dysfunction? J Urol 183: 1082–1086.
30. Cheng Y, Mansfield KJ, Allen W, Millard RJ, Burcher E, et al. (2012)
Correlation between cystometric volumes, ATP release, and pH in women with
overactive bladder versus controls. Neurourol Urodyn. doi: 10.1002/nau.22344.
31. Keiding R, Ho¨rde M, Gerhard W, Denmark E (1974) Recommended methods
for the determination of four enzymes in blood. Scand J Clin Lab Invest 1: 271–
74.
32. Sugaya K, Nishijima S, Kadekawa K, Miyazato M, Mukouyama H (2009)
Relationship between lower urinary tract symptoms and urinary ATP in patients
with benign prostatic hyperplasia or overactive bladder. Biomed Res 30: 287–94.
33. Moore KH, Richmond DH, Sutherst JR (1990) Urinary acidity in relation to
detrusor instability. Neurourol Urodynam 9: 331–332.
34. Egan JP (1975) Signal Detection Theory and ROC Analysis. In Series in
Cognitition and Perception. New York: Academic Press.
35. Kim JC, Park EY, Seo SI, Park YH, Hwang TK (2006) Nerve growth factor and
prostaglandins in the urine of female patients with overactive bladder. J Urol
175: 1773–6.
36. Antunes-Lopes T, Carvalho-Barros S, Cruz CD, Cruz F, Martins-Silva C (2011)
Biomarkers in overactive bladder: a new objective and noninvasive tool? Adv
Urol. doi: 10.1155/2011/382431.
37. Harvey RA, Skennerton DE, Newgreen D, Fry CH (2002) The contractile
potency of adenosine triphosphate and ecto-adenosine triphosphatase activity in
guinea pig detrusor and detrusor from patients with a stable, unstable or
obstructed bladder. J Urol 168: 1235–1239.
38. Silva I, Correia J, Ferreirinha F, Magalha˜es-Cardoso MT, Silva-Ramos M, et al.
(2011) Bladder overactivity due to global impairment of ecto-NTPDases in
humans with lower urinary tract disorders exhibiting unbalanced ATP/
adenosine formation. Auton Neurosci Basic Clinical 163: 49–50.
39. Castre´n E, Rantama¨ki T (2010) Role of brain-derived neurotrophic factor in the
aetiology of depression: implications for pharmacological treatment. CNS Drugs
24: 1–7.
40. Yu YB, Zuo XL, Zhao QJ, Chen FX, Yang J, et al. (2012) Brain-derived
neurotrophic factor contributes to abdominal pain in irritable bowel syndrome.
Gut 61: 685–694.
41. Munoz A, Gangitano DA, Smith CP, Boone TB, Somogyi GT (2010) Removal
of urothelium affects bladder contractility and release of ATP but not release of
NO in rat urinary bladder. BMC Urol 10: 10. doi: 10.1186/1471-2490-10-10.
42. Sadananda P, Shang F, Liu L, Mansfield KJ, Burcher E (2009) Release of ATP
from rat urinary bladder mucosa: role of acid, vanilloids and stretch.
Br J Pharmacol 158: 1655–1662.
ATP Is a Urinary Biomarker of Overactive Bladder
PLOS ONE | www.plosone.org 10 May 2013 | Volume 8 | Issue 5 | e64696
